JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aktien・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

38.99 -0.1

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

38.75

Max

39.11

Schlüsselkennzahlen
By Trading Economics
Einkommen	7.3M -123M
Verkäufe	3.7M 3.9M
EPS	-1.29
Gewinnspanne	-3,161.261
Angestellte	594
EBITDA	20M -122M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+109.53% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-445M 4B
Vorheriger Eröffnungskurs	39.09
Vorheriger Schlusskurs	38.99

Nachrichtenstimmung

By Acuity

50%

180 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

30.39 / 33.46 Unterstützung & Widerstand

Crinetics Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Crinetics Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

109.53% Vorteil

12-Monats-Prognose

Durchschnitt 86.43 USD 109.53%

Hoch 97 USD

Tief 67 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Crinetics Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Crinetics Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

30.39 / 33.46Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Stimmung

By Acuity

180 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.